IL26522A - Preparation of 4'-demethyl-epipodophyllotoxin - Google Patents
Preparation of 4'-demethyl-epipodophyllotoxinInfo
- Publication number
- IL26522A IL26522A IL2652266A IL2652266A IL26522A IL 26522 A IL26522 A IL 26522A IL 2652266 A IL2652266 A IL 2652266A IL 2652266 A IL2652266 A IL 2652266A IL 26522 A IL26522 A IL 26522A
- Authority
- IL
- Israel
- Prior art keywords
- epipodophyllotoxin
- bromide
- demethyl
- podophyllotoxin
- hydrogen
- Prior art date
Links
- FOVRGQUEGRCWPD-UHFFFAOYSA-N (5aR)-9t-beta-D-Glucopyranosyloxy-5t-(4-hydroxy-3,5-dimethoxy-phenyl)-(5ar,8at)-5,8,8a,9-tetrahydro-5aH-furo[3',4';6,7]naphtho[2,3-d][1,3]dioxol-6-on Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(OC3C(C(O)C(O)C(CO)O3)O)C3C2C(OC3)=O)=C1 FOVRGQUEGRCWPD-UHFFFAOYSA-N 0.000 title description 9
- YVCVYCSAAZQOJI-JHQYFNNDSA-N 4'-demethylepipodophyllotoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YVCVYCSAAZQOJI-JHQYFNNDSA-N 0.000 title description 9
- 238000002360 preparation method Methods 0.000 title description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 28
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 15
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 11
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 9
- 229960001237 podophyllotoxin Drugs 0.000 claims description 9
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- -1 epipodophyllotoxin halide Chemical class 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- VNDCSULMOTZMNT-KSRYTWCQSA-N (5ar,8ar,9r)-5-bromo-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(Br)[C@@H]3[C@@H]2C(OC3)=O)=C1 VNDCSULMOTZMNT-KSRYTWCQSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000007789 gas Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical group COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000035699 Distal ileal obstruction syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000010103 Podophyllin Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940068582 podophyllin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
•flimi |Π3 ΤϊΙΠΙ"! 'ΊΊ PATENT ATTORNEYS · D'DIOS ' 3 Ί 1 U PATENTS AND DESIGNS ORDINANCE SPECIFICATION Preparation of 4,*deaethyl-epipo0ophyllotoxin SAIDOZ ( a Sviss Body Corporate of Basle, Switzerland do hereby declare the nature of this invention and in what manner the same is to "be performed, to he particularly described and ascertained in and by the following statement :- Case 2209 The present invention relates to the production of an-alAayolic oorope«a&r- 4 •-demethyl-epipodophyllotoxin.
The present invention provides a process for the production of V-demethyl-epipodophyllotoxin of formula I, characterized in that podophyllotoxin is reaoted with hydrogen bromide or hydrogen chloride, the resulting epipodophyllotoxin halide of general formula II, in which Hal signifies a chlorine or bromine atom, is treated with hydrogen bromide and the resulting 4'-demethyl-epipodophyliotoxin bromide of formula III is hydrolyzed.
It was hitherto not possible to effect a seleotive ether-splitting in the 4' -position of epipodophyllotoxin or podophyllotoxin. Surprisingly it has now been found that a selective ether-splitting in the '-position of epipodophyllotoxin halides of general formula II, which are extremely sensitive to the aotion of hydrogen halides, may be effected with hydrogen bromide. As a result it is possible to produoe 4,-demethyl-epipodophyllotoxin by a simple process from the readily obtainable podophyllotoxin.
One method of effecting the process of the invention consists in that podophyllotoxin is treated with hydrogen bromide gas or hydrogen chloride gas in an inert solvent, e.g. ethylene chloride, chloroform or methylene chloride, containing some ether1, at -20° to +40°C, preferably at 0°C. The resulting solution of epipodophyllotoxin halide is then again treated with hydrogen bromide gas under the con - 3 - 26522/2 After washing out the excess hydrogen bromide with water, drying the organic phase and evaporating in a vacuum, 4'-demethyl-epipodophyllotoxin bromide may be purified by crystallization from an inert solvent, e.g. acetone, a mixture of acetone and ether, a mixture of acetone and a hydrocarbon or a halogenated hydrocarbon. The pure 4*-demethyl-epipodophyllo-toxin bromide is subsequently dissolved in a mixture of water and a water miacible organic solvent which does not react with 41-demethyl-epipodophyllotoxin bromide, e.g. acetone, and hydrolyzed at a reaction temperature between 20° and 80°C in the presence of a proton acceptor. Proton acceptors which may be used are the salts of weak acids, the aqueous solutions of which give a neutral reaction or such a weak basic reaction that no epimerization of the lactone ring on the C atom in the 3-position occurs, and the anions of which do not participate in undesired exchange reactions with the bromine atom, e.g. barium carbonate and calcium carbonate. 4'-demethyl-epipodophyllotoxin may be isolated in manner known per se and subsequently purified, e.g. by crystallization or chromatography. 4»-demethyl-epipodophyllotoxin is a solid, crystalline compound at room temperature. It may be used as intermediate in the synthesis of cytostatics of the llgnan type having a high therapeutic activity* '-demethyl-epipodophyllotoxin Itself, however, also has a selective inhibiting effect on dividing phenomena in the cell nucleus and its use is therefore indicated in cases where, for medical reasons, the slowing down or prevention of cell division or cell multiplication is - 3a - 26522/2 desirable. The compound prepared by the process of the invention, as opposed to other podophyllin derivatives, is especially characterized in that it tends not to have a general cytotoxic effect and tends not to produce side effects, e.g. nausea and vomiting. - 4 - 2209 The W» compound may be used as a pharmaceutical on its own or in the form of appropriate medicinal preparations for administration, e.g. enterally or parenterally. In order to produce suitable medicinal preparations the compound is worked up with organic or lnorganio adjuvants which are inert and physiologically acceptable. Examples of such adjuvants aret for tablets and drage'es : lactose, starch, talc and steario acid; for syrups : solutions of cane sugar, invert sugar and glucose; for injectable solutions : water, alcohols, glycerin and vegetable oils; for suppositories : natural or hardened oils and waxes.
The preparations may furthermore contain suitable preserving, stabilizing and wetting agents, solubilizers, sweetening and colouring substances and flavourings.
The term "in manner known per sew as used herein designates methods in. use or described in the literature on the subject.
In the following non-limitative Example^ all temperatures are indicated in degrees Centigrade. The melting and decomposition points were determined on a Kofler block. - 5 2209 E amgle^ 41 -demethyl-epipodophyllotoxin. a) 4' -demethyl-epipodophyllotoxin bromide. g of podophyllotoxin are dissolved in 200 ml of ethylene chloride and the solution is saturated with hydrogen bromide gas at 0° . After 1 minutes, washing is effected once with 200 ml of water, the organic phase is dried over sodium sulphate, filtered and the sodium sulphate washed with 50 ∞1 of ethylene chloride. 5 ml of ether are added to the resulting solution of epipodophyllotoxin bromide and after cooling to 0° the solution is saturated with hydrogen bromide gas. The solution is allowed to react at 0° and after 3, 5, 20 and 25 hours saturation with hydrogen bromide gas is again effected. After 28 hours washing is effected thrice, each time with 400 ml of water and after drying the organic phase with sodium sulphate evaporation is effected in a vacuum. 40 ml of warm acetone are poured on the slightly reddish residue, whereby crystallization occurs. Further purification is effected by crystallizing once more from acetone, whereby 4' -demethyl-epipodophyllotoxin bromide, having a melting point of I8O-I900, [a]2^= +16.3° (c m 0.612 in chloroform) and +15 ,0° (c «= 0.632 in acetone) is obtained. The compound melts with decomposition. b) 4' -demethyl-epipodophyllotoxin bromide. 220 g of pure podophyllotoxin are suspended in a mixture of 2000 ml of ethylene chloride and 200 ml of ether. 550 to 570 g of hydrogen bromide gas are passed whereby a clear solution results. This solution is allowed to stand at -5° for 23 hours and is then evaporated in a vacuum at a bath temperature of 25-300. 100 ml of hot acetone are added to the residue and evaporation is again effected in a vacuum. 300 ml of a boiling mixture of acetone and ligroin (3 ·' 2) are then added, stirring is effected whilst heating on a steam bath until a fine powder results which is allowed to crystallize at 8°. After filtering the precipitate with suction, washing with $00 ml of acetone/pentane (2 : 1) and drying in a vacuum are effected. This crude product ¾till contains polar material in accordance with thin layer chromatography and is therefore suspended in 1200 ml of hot acetone (does not dissolve completely), the volume of the solution is reduced to about 00 to 00 ml in a vacuum and allowed to crystallize at 8°. "After filtering the precipitate by suction, washing with 150 ml of acetone/pentane (2 : 1) and drying in a vacuum at 500, 4' -demethyl-epipodophyllotoxin bromide, no longer containing.by-products in accordance with thin layer chromatography, is obtained. c) 4' -demethyl-epipodophyllotoxin. 2.3 g of ' -demethyl-epipodophyllotoxin bromide are added to a suspension of 2 g of barium carbonate in 50 ml of acetone/water (1 : 1 ) and stirring is effected at 40° for one hour. The excess barium carbonate is subsequently filtered off, washing is effected with acetone and the acetone is removed from the filtrate in a vacuum and the organic solvent evaporated in a vacuum after drying over sodium sulphate. Crystallization of the residue from chloroform and from methanol or ethanol yields pure 4' -demethyl-epipodophyllotoxin, having a melting point of 228-230°, [a]2°» -69.8° (c « O.630 in chloro orm) .
Claims (1)
1. characterized in that podophyllotoxin is reacted with hydrogen bromide or hydro general in which Hal signifies a chlorine or bromine is treated with hydrogen bromide and the resulting podophyllotoxin bromide of formula III 9 220 is A process according to Claim in which the epipodohyllotoxin bromide is produced in a single in that podophyllotoxin is reacted directl with hydrogen process acoording to Claim in which the hydrolysis is effected at a temperature between and in the presenoe of a proton A process according to Claim in which the reaction of podophyllotoxin with hydrogen bromide or hydrogen and the subsequent reaction of the epipodophyllotoxin halide of general formula II with hydrogen bromide are effected at a temperature between and A process according to Claim in which the reaction is effeoted at a temperature between and A process for the production of substantially as herein described with reference to the 10 whenever produced the process claimed in one of the preceding Pharmaceutical compositions in addition to a physiologically inert yHotoxin For the Applicants AND PARTNERS insufficientOCRQuality
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH747068A CH472403A (en) | 1965-09-21 | 1965-09-21 | Process for the preparation of a 4'-demethyl-epipodophyllotoxin |
| CH1301665A CH459255A (en) | 1965-09-21 | 1965-09-21 | Process for the preparation of new 4'-demethyl-epipodophyllotoxin halides |
| CH1301865A CH459257A (en) | 1965-09-21 | 1965-09-21 | Process for the preparation of 4'-demethyl-epipodophyllotoxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL26522A true IL26522A (en) | 1970-06-17 |
Family
ID=27175799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL2652266A IL26522A (en) | 1965-09-21 | 1966-09-19 | Preparation of 4'-demethyl-epipodophyllotoxin |
Country Status (9)
| Country | Link |
|---|---|
| AT (1) | AT281300B (en) |
| BE (1) | BE687089A (en) |
| BR (1) | BR6683006D0 (en) |
| CH (3) | CH459257A (en) |
| FI (1) | FI44411B (en) |
| FR (2) | FR1502813A (en) |
| GB (1) | GB1145909A (en) |
| IL (1) | IL26522A (en) |
| SE (1) | SE327416B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5463040A (en) * | 1994-06-28 | 1995-10-31 | Teva Pharmaceutical Industries, Ltd. | Method of preparing etoposide |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8307614D0 (en) * | 1983-03-18 | 1983-04-27 | Pharma Medica As | Treatment of genital warts |
| DE69033342T2 (en) * | 1989-02-23 | 2000-05-11 | University Of North Carolina At Chapel Hill, Chapel Hill | ETOPOSIDE ANALOGS |
-
1965
- 1965-09-21 CH CH1301865A patent/CH459257A/en unknown
- 1965-09-21 CH CH1301665A patent/CH459255A/en unknown
- 1965-09-21 CH CH747068A patent/CH472403A/en not_active IP Right Cessation
-
1966
- 1966-07-21 GB GB3289166A patent/GB1145909A/en not_active Expired
- 1966-09-19 BE BE687089D patent/BE687089A/xx unknown
- 1966-09-19 FI FI245566A patent/FI44411B/fi active
- 1966-09-19 IL IL2652266A patent/IL26522A/en unknown
- 1966-09-19 FR FR76825A patent/FR1502813A/en not_active Expired
- 1966-09-20 BR BR18300666A patent/BR6683006D0/en unknown
- 1966-09-20 SE SE1261866A patent/SE327416B/xx unknown
- 1966-09-20 AT AT883566A patent/AT281300B/en not_active IP Right Cessation
- 1966-12-16 FR FR87743A patent/FR6307M/fr not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5463040A (en) * | 1994-06-28 | 1995-10-31 | Teva Pharmaceutical Industries, Ltd. | Method of preparing etoposide |
Also Published As
| Publication number | Publication date |
|---|---|
| FR6307M (en) | 1968-09-16 |
| GB1145909A (en) | 1969-03-19 |
| BE687089A (en) | 1967-03-20 |
| CH459257A (en) | 1968-07-15 |
| DE1543874A1 (en) | 1970-01-02 |
| CH459255A (en) | 1968-07-15 |
| AT281300B (en) | 1970-05-11 |
| FI44411B (en) | 1971-08-02 |
| FR1502813A (en) | 1967-11-24 |
| BR6683006D0 (en) | 1973-12-27 |
| SE327416B (en) | 1970-08-24 |
| CH472403A (en) | 1969-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR930009818B1 (en) | Process for preparing torasemide stable variant and pharmaceutical composition thereof | |
| US2446102A (en) | Complex salts of streptomycin and process for preparing same | |
| Bílik | Reactions of Saccharides Catalyzed by Molybdate Ions. III.* Preparation of L-Glucose by Epimerization of L-Mannose or L-Mannose Phenylhydrazone | |
| Schaffer et al. | Structure of 5-Aldo-1, 2-O-isopropylidene-D-xylo-pentofuranose1 | |
| Wolfrom et al. | Keto-fructose pentaacetate | |
| IL26522A (en) | Preparation of 4'-demethyl-epipodophyllotoxin | |
| US3998807A (en) | Arabinofuranosyl cytosines and methods of making | |
| Lemieux et al. | REACTIONS OF 2-ACETOXY-4, 6-DI-O-ACETYL-3-O-(2, 6-DICHLOROBENZOYL)-d-GLUCAL, TRI-O-ACETYL-3-DEOXY-α-d-erythro-HEX-2-ENOPYRANOSYL CHLORIDE, AND RELATED COMPOUNDS | |
| Pacsu | ACTION OF TITANIUM TETRACHLORIDE ON DERIVATIVES OF SUGARS. IV. TRANSFORMATION OF HEPTA-ACETYL-BETA-METHYLCELLOBIOSIDE TO THE ALPHA FORM AND THE PREPARATION OF ALPHA-METHYLCELLOBIOSIDE1 | |
| US3792040A (en) | Acyl derivatives of o2,2'-anhydro-1-(beta-d-arabinofuranosyl)-cytosines and methods of preparing | |
| NO151748B (en) | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL ACCEPTABLE, NON-SOLVATED, WATER-FREE, GAMMA CRYSTALLINIC FORM OF SODRIM-7- (D-ALFA-FORMYLOXY-ALFA-PHENYLACETAMIDO) -3- (1-METHYL-METHYL-YL-METHYL-H-METHYL-YL-METHYL-1-METHYL-METHYL-METHYL) 3-cephem-4-carboxylate | |
| Schmidt-Nickels et al. | Researches on pyrimidines. CXVIII. Molecular rearrangements in the thymine series | |
| Hilbert | Synthetic Nucleosides—Some 1-Glycosidouracils | |
| Hockett et al. | Relations between rotatory power and structure in the sugar group. XXXIII. The alpha and beta methyl pyranosides of l-fucose (l-galactomethylose) and their triacetates | |
| US3583992A (en) | 1-methyl-d-lysergic acid-dihydroxy-alkyl-amides | |
| US2390395A (en) | Sorbitan and process for making the same | |
| Frush et al. | Amides of glucuronic, galacturonic, and mannuronic acids | |
| ONODERA et al. | Synthesis of 2-Amino-2-deoxy-β-D-glucosides via 3, 4, 6-Tri-O-acetyl-2-benzyl-sulfonamido-2-deoxy-α-D-glucopyranosyl Bromide | |
| BONNER | The Anomers of Tetra-O-acetyl-2-deoxy-D-glucose | |
| NO164794B (en) | Deadlock. | |
| Dale | Relations Between Rotatory Power and Structure in the Sugar Group. Xx. Two Isomeric Crystalline Compounds of d-MANNOSE with Calcium CHLORIDE1 | |
| SU793404A3 (en) | Method of preparing vincinic acid derivatives or their salts or their quaternary salts | |
| Stewart et al. | A Convenient Synthesis of β-Chloropropionitrile | |
| Wolfrom et al. | The Free Aldehyde Form of Fucose Tetraacetate | |
| PL56520B1 (en) |